Pharmaceutical Contract Development And Manufacturing Market

Pharmaceutical Contract Development and Manufacturing Market By Service [Pharmaceutical Manufacturing Services (API, FDF), Drug Development Services, Biologics Development], End User [Big & Generic Pharmaceutical Companies] – Global Forecast to 2027

Report ID: MRHC -104477
Pages: 200
Mar-2021
Formats*: PDF
Category: Healthcare
Delivery: 2 to 4 Hours

COVID-19

This report provides pre & post COVID-19 market estimates.

Download sample here

The pharmaceutical contract development and manufacturing market is expected to grow at a CAGR of 6.5% from 2020 to 2027 to reach $134.23 billion by 2027. The complex structure for manufacturing pharmaceuticals, increasing investments in pharmaceutical R&D, growing outsourcing of clinical trials, and the outbreak of the COVID-19 pandemic are some of the major drivers for the growth of this market. In addition, the rising demand for generic medicines & biologics, growing demand for cell & gene therapies, and increasing pharmaceutical outsourcing support the growth of this market. However, service quality & IPR issues, lack of skilled professionals, and introduction of serialization are the factors expected to hinder the growth of the pharmaceutical contract development and manufacturing market during the forecast period.

COVID-19 Impact on the Pharmaceutical Contract Development and Manufacturing Market

The recent outbreak of COVID-19 has impacted the healthcare market. The pharmaceutical contract development and manufacturing industry has experienced a positive impact due to this pandemic. The outbreak has catalyzed the demand for pharmaceuticals and has stirred the development of corona-related vaccines, antiviral vaccines, antibody therapy, and various pharmaceutical products. This has urged pharmaceutical organizations to hire contract development and manufacturing organizations for pharmaceutical drug development & manufacturing to sustain their business.

The demand for both high quality and high volume CGMP drug substance and drug product manufacturing services has soared, particularly for CDMOs able to support a wide range of COVID vaccine technologies and, to a lesser extent, therapeutic monoclonal antibody products.

Most pharmaceutical companies, CROs, and research institutes are working together to translate research into effective pharmaceutical products. For instance, in August 2020, Catalent Inc. (U.S.) signed an agreement with AstraZeneca PLC (U.K.) to expand manufacturing support for the University of Oxford’s adenovirus vector-based COVID-19 vaccine AZD1222. In September 2020, Thermo Fisher Scientific Inc. (U.S.) partnered with Inovio Pharmaceuticals, Inc. (U.S.) to manufacture INOVIO's DNA COVID-19 vaccine candidate INO-4800 and to enhance the commercial production of INO-4800.

Pharmaceutical Contract Development And Manufacturing Market

Click here to: Get Free Sample Pages of this Report

Increasing investments in the pharmaceutical R&D support the market growth

The pharmaceutical industry is largely driven by scientific discovery and development, in conjunction with toxicological and clinical experience. Also, healthcare R&D activities have significantly increased with rising funding from various government organizations. This funding is mainly driven by rising health care concerns, complexities in clinical trials, and drug failure in early-phase studies.

Governments in developed and developing nations are offering to fund the propagation of biotechnology and biopharmaceutical research. For instance, the Indian government launched 'Pharma Vision 2020' to increase the production capacities of biopharmaceuticals by reducing the approval time for new facilities. Also, the government decided in favor of 100% foreign direct investment in the pharmaceutical industry, which is expected to increase investments in R&D activities. Similarly, in the U.S., the National Institute of Health (NIH) collaborated with 11 biopharmaceutical companies to launch the Partnership for Accelerating Cancer Therapies (PACT) to develop immunotherapy for cancers. The program involved a total investment of USD 215 million.

Further, pharmaceutical companies have also increased their spending on R&D. The extent of pharmaceutical R&D spending serves as an important metric to show a company’s commitment to finding new drugs. At present, the global pharmaceutical industry has the second-highest R&D intensity, i.e. expenditure as a share of any sector's sales measures. Thus, the increasing investments from the government for pharmaceutical R&D is likely to boost outsourcing, thereby accelerating pharmaceutical contract development & manufacturing market growth.

Growing consolidation in the market, an ongoing trend

Due to growing pressure on leading pharmaceutical players, complex drug development process, growing number of patents expiring, increasing R&D costs, and the increasing prevalence of chronic diseases are some of the factors making outsourcing essential.

CDMOs offer the convenience of time and cost due to the inherent nature of dealing with a single entity. The relationship also creates opportunities for the pharmaceutical CDMOs to sell more services to the same customer and locking in products at earlier stages of their life cycles.

Due to the growing pressure on the industry’s leading players to follow stringent regulatory timelines and lack of human clinical trial data, pharmaceutical giants are entering into collaborations, partnerships, and agreements to jointly broaden their services offered across all drug development & pharmaceutical manufacturing processes:

In June 2020, Catalent Inc. (U.S.) collaborated with Moderna, Inc. (U.S.) for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate (mRNA-1273).
In April 2020, ICON plc (Ireland) agreed with Pfizer Inc. (U.S.) to supply drug and device development and commercialization services.

Click here to: Get a Free Request Sample Copy of this report

Key Findings in the Pharmaceutical Contract Development and Manufacturing Market Study:

Pharmaceutical manufacturing services generated a large proportion of revenue compared to other services

The large share of this segment is mainly attributed to the use of advanced technologies & manufacturing skills, the growing need to reduce manufacturing cost, the requirement for high-quality bulk manufacturing, and the growing demand for generic drugs.

Pharmaceutical API contract manufacturing services are estimated to account for the largest share of the pharmaceutical contract manufacturing services market in 2020

The need for the reduction in the cost of production of APIs, growing number of initiatives undertaken by pharmaceutical companies, increasing investments in API manufacturing services, and growing need to reduce the time required for the drug development process are expected to drive the growth of the pharmaceutical API contract manufacturing services segment.

In 2020, the big pharmaceutical companies segment to dominate pharmaceutical contract development and manufacturing market

The major share of this segment is primarily attributed to the growing prevalence of various infectious diseases, growing need for state-of-the-art processes & production technologies, and the rising cost of clinical trials and early development studies.

Asia-Pacific: Fastest growing regional market

In 2020, North America is estimated to command the largest share of the pharmaceutical contract development and manufacturing market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. However, Asia-Pacific will be the fastest-growing regional market due to the growing manufacturing sector, favorable government regulations, increasing emphasis on off-patent drugs, and highly skilled workforce in the region. In addition, the increase in outsourcing activities in countries like India and China due to lower costs and availability of qualified healthcare professionals are the other key factors propelling the growth of the Asia-Pacific pharmaceutical contract development and manufacturing market.

Key Players

The report includes a competitive landscape based on an extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past four years (2017-2020). The key players profiled in the pharmaceutical contract development and manufacturing market report are Thermo Fisher Scientific Inc. (U.S.), Catalent Inc. (U.S.), PPD Inc. (U.S.), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Vetter Pharma-Fertigung GmbH & Co. KG (Germany), AbbVie Inc. (U.S.), Synoes Health, Inc. (U.S.), Piramal Enterprises Limited (India), Almac Group (U.K.), Albany Molecular Research Inc. (U.S.), Fareva Holding SA (France), and Jubilant Life Sciences Limited (India).

Scope of the Report:

Global Pharmaceutical Contract Development and Manufacturing Market, by Service

Pharmaceutical Manufacturing Services
- Pharmaceutical API Manufacturing Services
- Pharmaceutical FDF Manufacturing Services
  - Parenteral/Injectable Manufacturing Services
  - Tablet Manufacturing Services
  - Capsule Manufacturing Services
  - Oral Liquid Manufacturing Services
  - Other Formulations Manufacturing Services
Drug Development Services
Biologics Manufacturing Services
- Biologics API Manufacturing Services
- Biologics API Manufacturing Services

Global Pharmaceutical Contract Development and Manufacturing Market, by End User

Big Pharmaceutical Companies
Small and Med-Size Pharmaceutical Companies
Generic Pharmaceutical Companies

Global Pharmaceutical Contract Development and Manufacturing Market, by Geography

North America
- U.S.
- Canada
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe (RoE)
Asia-Pacific (APAC)
- China
- Japan
- India
- Rest of APAC (RoAPAC)
Latin America
Middle East & Africa

Key questions answered in the report:

What is the focus of the pharmaceutical contract development and manufacturing market?

The pharmaceutical contract development and manufacturing market covers the market size & forecasts the various pharmaceutical manufacturing services, drug development services, and biologics manufacturing services used by the pharmaceutical industry. The pharmaceutical contract development and manufacturing market studied in this report involves the value analysis of various segments and sub-sections of pharmaceutical contract development and manufacturing at the regional and country levels.

What is the value of revenue generated from the pharmaceutical contract development and manufacturing services across the globe? At what rate their demand expected to grow for the next 5-7 years?

The pharmaceutical contract development and manufacturing market is projected to reach $134.23 billion by 2027, at a CAGR of 6.5% during the forecast period.

Which service type is estimated to hold the major share of the market?

The pharmaceutical manufacturing services segment is estimated to account for the largest share in 2020. The use of advanced technologies, the growing need to reduce manufacturing cost, the requirement for high-quality bulk manufacturing, and the growing demand for generic drugs are major factors supporting the largest share.

Which end-user segment of the market is projected to create more traction in the pharmaceutical contract development and manufacturing market?

The generic pharmaceutical companies segment is projected to register the fastest CAGR during the forecast period due to growing demand for generic medicines, increasing competition in the generic market leading to pricing pressure, and inclination towards cutting-edge technologies offered by contract development and manufacturing companies.

What are the key factors supporting the growth of this market? What are the major opportunities for existing market players and new entrants in the pharmaceutical contract development and manufacturing market?

The complex manufacturing requirements, increasing investments in pharmaceutical R&D, and the COVID-19 pandemic are the key factors driving the growth of this market. Further, rising demand for generic medicines and biologics, growing demand for cell and gene therapies, and increasing pharmaceutical outsourcing offer significant growth opportunities for the players operating in the pharmaceutical contract development and manufacturing market.

Who are the major players operating in the pharmaceutical contract development and manufacturing market?

The key players operating in the pharmaceutical contract development and manufacturing market are Thermo Fisher Scientific Inc. (U.S.), Catalent Inc. (U.S.), PPD Inc. (U.S.), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Vetter Pharma-Fertigung GmbH & Co. KG (Germany), AbbVie Inc. (U.S.), Synoes Health, Inc. (U.S.), Piramal Enterprises Limited (India), Almac Group (U.K.), Albany Molecular Research Inc. (U.S.), Fareva Holding SA (France), and Jubilant Life Sciences Limited (India) among others.

Which regions/countries are expected to offer significant growth opportunities for the vendors operating in the pharmaceutical contract development and manufacturing market?

Emerging economies like China and India are projected to offer significant growth opportunities for the vendors in this market with accelerated economic growth and increasing incidence of chronic diseases. The lower cost of outsourcing activities and availability of skilled professionals are also propelling the growth of the market in these countries.

Download Sample

1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency

2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-Up Approach
2.3.1.2. Top-Down Approach
2.3.1.3. Growth Forecast
2.3.2. Market Share Analysis
2.4. Assumptions for the Study
2.5. Limitations for the Study

3. Executive Summary

4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Complex Manufacturing Requirements
4.2.2. Increasing Investments in Pharmaceutical R&D
4.2.3. Inclination Towards Cutting Edge Technologies
4.2.4. Impact of COVID-19 Pandemic
4.3. Restraint
4.3.1. Product Quality & IPR Issues
4.4. Opportunities
4.4.1. Increasing Pharmaceutical Outsourcing
4.4.2. Rising Demand for Generic Medicines and Biologics
4.4.3. Growing Demand for Cell and Gene Therapies
4.5. Challenges
4.5.1. Dearth of Skilled Professionals
4.5.2. Introduction of Serialization
4.6. Trends
4.6.1. Growing Consolidation
4.6.2. Virtual Business Models

5. Pharmaceutical Contract Development & Manufacturing Market, by Service
5.1. Introduction
5.2. Pharmaceutical Manufacturing Services
5.2.1. Pharmaceutical API Manufacturing Services
5.2.2. Pharmaceutical FDF Manufacturing Services
5.2.2.1. Parenteral/Injectable Manufacturing Services
5.2.2.2. Tablet Manufacturing Services
5.2.2.3. Capsule Manufacturing Services
5.2.2.4. Oral Liquid Manufacturing Services
5.2.2.5. Other Formulations Manufacturing Services
5.3. Drug Development Services
5.4. Biologics Development Services
5.4.1. Biologics API Manufacturing Services
5.4.2. Biologics FDF Manufacturing Services

6. Global Pharmaceutical Contract Development & Manufacturing Market, by End User
6.1. Introduction
6.2. Big Pharmaceutical Companies
6.3. Small & Mid-Size Pharmaceutical Companies
6.4. Generic Pharmaceutical Companies

7. Global Pharmaceutical Contract Development & Manufacturing Market, by Geography
7.1. Introduction
7.2. North America
7.2.1. U.S.
7.2.2. Canada
7.3. Europe
7.3.1. Germany
7.3.2. U.K.
7.3.3. France
7.3.4. Italy
7.3.5. Spain
7.3.6. Rest of Europe
7.4. Asia-Pacific
7.4.1. Japan
7.4.2. China
7.4.3. India
7.4.4. Rest of Asia-Pacific
7.5. Latin America
7.6. Middle East & Africa

8. Competitive Landscape
8.1. Introduction
8.2. Key Growth Strategies
8.3. Competitive Benchmarking
8.4. Market Share Analysis (2019)

9. Company Profiles (Business Overview, Financial Overview, Service Portfolio, & Strategic Developments)
9.1. Thermo Fisher Scientific Inc.
9.2. Catalent, Inc.
9.3. PPD Inc.
9.4. Lonza Group Ltd
9.5. Recipharm AB
9.6. Vetter Pharma-Fertigung GmbH & Co. KG.
9.7. AbbVie Inc.
9.8. Syneos Health, Inc.
9.9. Piramal Enterprises Limited
9.10. Almac Group
9.11. Albany Molecular Research Inc. (AMRI )
9.12. Fareva Holding SA
9.13. Jubilant Life Sciences Limited

10. Appendix
10.1. Questionnaire
10.2. Available Customization

List of Tables

Table 1 Global Pharmaceutical Contract Development and Manufacturing Market Drivers: Impact Analysis (2020–2027)
Table 2 Global Pharmaceutical Contract Development & Manufacturing Market Restraints: Impact Analysis (2020–2027)
Table 3 Number of COVID-19 Cases, by Country
Table 4 Global Pharmaceutical Contract Development and Manufacturing Market Size, by Service, 2018–2027 (USD Million)
Table 5 Global Pharmaceutical Contract Development and Manufacturing Market Size for Pharmaceutical Manufacturing Services, by Type, 2018–2027 (USD Million)
Table 6 Global Pharmaceutical Contract Development and Manufacturing Market Size for Pharmaceutical Manufacturing, by Region/Country, 2018–2027 (USD Million)
Table 7 Key Companies Offering Pharmaceutical API Contract Manufacturing Services
Table 8 Global Pharmaceutical Contract Manufacturing Market Size for API Manufacturing, by Region/Country, 2018–2027 (USD Million)
Table 9 Key Companies Offering Pharmaceutical FDF Contract Manufacturing Services
Table 10 Global Pharmaceutical Contract Manufacturing Market Size for FDF Manufacturing, by Region/Country, 2018–2027 (USD Million)
Table 11 Global Pharmaceutical Contract Development and Manufacturing Market Size for Drug Development, by Region/Country, 2018–2027 (USD Million)
Table 12 Global Biologics Contract Development Services Market Size, by Type, 2018–2027 (USD Million)
Table 13 Global Pharmaceutical Contract Development & Manufacturing Market Size for Biologics Development, by Region/Country, 2018–2027 (USD Million)
Table 14 Key Players Offering Biologics API Manufacturing Services
Table 15 Global Biologics Contract Manufacturing Market Size for API, by Region/Country, 2018–2027 (USD Million)
Table 16 Key Players Offering Biological FDF Services
Table 17 Global Biologics Contract Development Market Size for FDF Services, by Region/Country, 2018–2027 (USD Million)
Table 18 Global Pharmaceutical Contract Development & Manufacturing Market, by End User, 2018-2020 (USD Million)
Table 19 Global Pharmaceutical Contract Development & Manufacturing Market for Big Pharmaceutical Companies, 2018–2027 (USD Million)
Table 20 Global Pharmaceutical Contract Development & Manufacturing Market for Small & Mid-Size Pharmaceutical Companies, 2018–2027 (USD Million)
Table 21 Global Pharmaceutical Contract Development & Manufacturing Market for Generic Pharmaceutical Companies, 2018–2027 (USD Million)
Table 22 Global Pharmaceutical Contract Development & Manufacturing Market Size, by Country/ Region, 2018–2027 (USD Million)
Table 23 North America: Pharmaceutical Contract Development & Manufacturing Market Size, by Country, 2018–2027 (USD Million)
Table 24 North America: Pharmaceutical Contract Development & Manufacturing Market Size, by Services, 2018–2027 (USD Million)
Table 25 North America: Pharmaceutical Contract Manufacturing Services Market Size, By Type, 2018–2027 (USD Million)
Table 26 North America: Biologics Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 27 North America: Pharmaceutical Contract Development & Manufacturing Market Size, by End User, 2018–2027 (USD Million)
Table 28 Key Developments by Companies with Respect to COVID-19 Vaccine
Table 29 U.S.: Pharmaceutical Contract Development & Manufacturing Market Size, by Service, 2018–2027 (USD Million)
Table 30 U.S.: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 31 U.S.: Biologics Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 32 U.S.: Pharmaceutical Contract Development & Manufacturing Market Size, by End User, 2018–2027 (USD Million)
Table 33 Canada: Pharmaceutical Contract Development & Manufacturing Market Size, by Service, 2018–2027 (USD Million)
Table 34 Canada: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 35 Canada: Biologics Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 36 Canada: Pharmaceutical Contract Development & Manufacturing Market Size, by End User, 2018–2027 (USD Million)
Table 37 Europe: Pharmaceutical Contract Development & Manufacturing Market Size, by Country, 2018–2027 (USD Million)
Table 38 Europe: Pharmaceutical Contract Development & Manufacturing Market Size, by Service, 2018–2027 (USD Million)
Table 39 Europe: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 40 Europe: Biologics Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 41 Europe: Pharmaceutical Contract Development & Manufacturing Market Size, by End User, 2018–2027 (USD Million)
Table 42 Germany: Pharmaceutical Contract Development & Manufacturing Market Size, by Service, 2018–2027 (USD Million)
Table 43 Germany: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 44 Germany: Biologics Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 45 Germany: Pharmaceutical Contract Development & Manufacturing Market Size, by End User, 2018–2027 (USD Million)
Table 46 Key Developments to Support Drug Development Services in the U.K.
Table 47 U.K.: Pharmaceutical Contract Development & Manufacturing Market Size, by Service, 2018–2027 (USD Million)
Table 48 U.K.: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 49 U.K.: Biologics Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 50 U.K.: Pharmaceutical Contract Development & Manufacturing Market Size, by End User, 2018–2027 (USD Million)
Table 51 France: Pharmaceutical Contract Development & Manufacturing Market Size, by Service, 2018–2027 (USD Million)
Table 52 France: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 53 France: Biologics Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 54 France: Pharmaceutical Contract Development & Manufacturing Market Size, by End User, 2018–2027 (USD Million)
Table 55 Italy: Pharmaceutical Contract Development & Manufacturing Market Size, by Service, 2018–2027 (USD Million)
Table 56 Italy: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 57 Italy: Biologics Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 58 Italy: Pharmaceutical Contract Development & Manufacturing Market Size, by End User, 2018–2027 (USD Million)
Table 59 Spain: Pharmaceutical Contract Development & Manufacturing Market Size, by Service, 2018–2027 (USD Million)
Table 60 Spain: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 61 Spain: Biologics Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 62 Spain: Pharmaceutical Contract Development & Manufacturing Market Size, by End User, 2018–2027 (USD Million)
Table 63 Clinical Trials in the European Countries (As of 2018)
Table 64 RoE: Pharmaceutical Contract Development & Manufacturing Market Size, by Service, 2018–2027 (USD Million)
Table 65 RoE: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 66 RoE: Biologics Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 67 RoE: Pharmaceutical Contract Development & Manufacturing Market Size, by End User, 2018–2027 (USD Million)
Table 68 Asia-Pacific: Pharmaceutical Contract Development & Manufacturing Market Size, by Country, 2018–2027 (USD Million)
Table 69 Asia-Pacific: Pharmaceutical Contract Development & Manufacturing Market Size, by Service, 2018–2027 (USD Million)
Table 70 Asia-Pacific: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 71 Asia-Pacific: Biologics Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 72 Asia-Pacific: Pharmaceutical Contract Development & Manufacturing Market Size, by End User, 2018–2027 (USD Million)
Table 73 Japan: Pharmaceutical Contract Development & Manufacturing Market Size, by Service, 2018–2027 (USD Million)
Table 74 Japan: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 75 Japan: Biologics Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 76 Japan: Pharmaceutical Contract Development & Manufacturing Market Size, by End User, 2018–2027 (USD Million)
Table 77 China: Pharmaceutical Contract Development & Manufacturing Market Size, by Service, 2018–2027 (USD Million)
Table 78 China: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 79 China: Biologics Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 80 China: Pharmaceutical Contract Development & Manufacturing Market Size, by End User, 2018–2027 (USD Million)
Table 81 India: Pharmaceutical Contract Development & Manufacturing Market Size, by Service, 2018–2027 (USD Million)
Table 82 India: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 83 India: Biologics Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 84 India: Pharmaceutical Contract Development & Manufacturing Market Size, by End User, 2018–2027 (USD Million)
Table 85 Cancer Incidence (Number of Cases): 2018-2040
Table 86 RoAPAC: Pharmaceutical Contract Development & Manufacturing Market Size, by Service, 2018–2027 (USD Million)
Table 87 RoAPAC: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 88 RoAPAC: Biologics Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 89 RoAPAC: Pharmaceutical Contract Development & Manufacturing Market Size, by End User, 2018–2027 (USD Million)
Table 90 Latin America: Pharmaceutical Contract Development & Manufacturing Market Size, by Service, 2018–2027 (USD Million)
Table 91 Latin America: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 92 Latin America: Biologics Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 93 Latin America: Pharmaceutical Contract Development & Manufacturing Market Size, by End User, 2018–2027 (USD Million)
Table 94 Middle East & Africa: Pharmaceutical Contract Development & Manufacturing Market Size, by Service, 2018–2027 (USD Million)
Table 95 Middle East & Africa: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 96 Middle East & Africa: Biologics Manufacturing Services Market Size, by Type, 2018–2027 (USD Million)
Table 97 Middle East & Africa: Pharmaceutical Contract Development & Manufacturing Market Size, by End User, 2018–2027 (USD Million)
Table 98 Recent Developments, by Company, 2017–2020

List of Figures

Figure 1 Key Stakeholders
Figure 2 Research Process
Figure 3 Key Secondary Sources
Figure 4 Primary Research Techniques
Figure 5 Key Executives Interviewed
Figure 6 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 7 Market Size Estimation
Figure 8 Global Pharmaceutical Contract Development & Manufacturing Market Size, by Service, 2020 VS. 2027 (USD Million)
Figure 9 Global Pharmaceutical Manufacturing Services Market Size, by Type, 2020 Vs. 2027 (USD Million)
Figure 10 Big Pharmaceutical Companies to Dominate the Pharmaceutical Contract Development & Manufacturing Market, by End User (2020–2027)
Figure 11 Pharmaceutical Contract Development & Manufacturing Market, by Region
Figure 12 Market Dynamics
Figure 13 Number of Biologics Approved: 2010-2018
Figure 14 Worldwide Sale for Generics Drugs (2010-2019)
Figure 15 Global Medicine Spending (%) (2013 VS 2021)
Figure 16 Global Pharmaceutical Contract Development and Manufacturing Market Size, by Service, 2020–2027 (USD Million)
Figure 17 Number of Biologics Approved: 2010-2018
Figure 18 Global Pharmaceutical Contract Development & Manufacturing Market, by Region, 2020–2027 (USD Million)
Figure 19 North America: Snapshot
Figure 20 Europe: Snapshot
Figure 21 Number of Clinical Trial Sites: 2017
Figure 22 Biosimilar Consumption in Italy (% on Total for Top 7 EU Countries): 2018
Figure 23 Cancer Incidence by Country: 2018-2040 (Number of Cases)
Figure 24 Asia-Pacific: Snapshot
Figure 25 Number of Coronavirus Cases in Japan: 2020
Figure 26 Number of Clinical Trials in China: 2016-2018
Figure 27 Key Growth Strategies Adopted by Leading Players, 2017–2020
Figure 28 Pharmaceutical Contract Development & Manufacturing Services: Competitive Benchmarking
Figure 29 Market Share Analysis: Pharmaceutical Contract Development & Manufacturing Industry, 2019
Figure 30 Thermo Fisher Scientific Inc.: Financial Overview (2019)
Figure 31 Catalent Inc.: Financial Overview (2020)
Figure 32 PPD Inc.: Financial Overview (2019)
Figure 33 Lonza Group Ltd: Financial Overview (2019)
Figure 34 Recipharm AB: Financial Overview (2019)
Figure 35 AbbVie Inc.: Financial Overview (2019)
Figure 36 Syneos Health, Inc.: Financial Overview (2019)
Figure 37 Piramal Enterprises Limited.: Financial Overview (2020)
Figure 38 Jubilant Life Sciences Limited.: Financial Overview (2020)

Download Sample

Full Name:

Name can only consist of alphabets.

Please provide your full name.

Email:

Please provide valid email address.

Please provide your email address.

Job Title:

Please provide your job title.

Company:

Please provide your company name.

City:

Please provide your company name.

Phone Number

Please provide valid phone number.

Please provide your phone number.

Specific Interest

Please enter minimum 10 characters.

Captcha:

Please enter Captcha.

Please enter valid Captcha.

This website is secure and we do not share your personal information with any third party. Privacy Policy

SELECT PDF LICENSE

Single User 10% Discount

$ 3757.5 ~~$ 4175.00~~ With the help of Single User License, only an individual can use our report either electronically or online. The right to use of the report should be confined only to one authorized computer. Upon buying single user license, buyer must provide the names and email ids of the authorized users of this report.

Multiple Users 15% Discount

$ 4993.75 ~~$ 5875.00~~
Multi-User license permits to access the report from five authorized computers. It does not permit you to share the report with other divisions and subsidiaries of the same company. Upon buying multi-user license, buyer must provide the names and email ids of the authorized users of this report. (Recommended)

Corporate User 20% Discount

$ 6300 ~~$ 7875.00~~ With corporate use license, the complete or part of the content of the report can be shared or made available to other persons, other divisions and subsidiaries of same company. However, reproduction or redistribution of the report is prohibited without the prior permission of Meticulous Research.

Enquire

Check Discount

Request Sample

Speak to Analyst